Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data
You may also be interested in...
AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR
The PD-L1 inhibitor showed efficacy in the neoadjuvant/adjuvant setting, where Merck is developing Keytruda as well. BMS’s Opdivo was the first to win approval in neoadjuvant NSCLC.
Questions Overshadow Roche’s Bid To Make Tecentriq First Adjuvant Liver Cancer Treatment
Despite recording the first success for an adjuvant drug therapy in hepatocellular carcinoma, Roche is likely to need longer-term safety and efficacy data before attempting a filing.
Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers
Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.